For generations, sickle cell disease has meant recurring pain, hospital visits, organ damage, and shortened lives for many Black families. Today, new research is changing what may be possible. Scientists are no longer focused only on managing symptoms. They are learning how to alter the biological process that causes red blood cells to sickle.
A major development came in July 2026, when the Food and Drug Administration expanded approval of Casgevy, the first CRISPR based gene editing therapy for sickle cell disease, to children age two and older who experience recurring vaso occlusive crises. The treatment had previously been approved for patients age 12 and older.
Casgevy uses a patient’s own blood stem cells. Scientists edit those cells so the body produces more fetal hemoglobin, which helps prevent red blood cells from becoming rigid, curved, and capable of blocking blood flow. The edited cells are returned to the patient following intensive chemotherapy that prepares the bone marrow.
In the pediatric trial reviewed by the FDA, all eight children who could be evaluated achieved the main effectiveness goal. They experienced no severe vaso occlusive crises for at least 12 consecutive months during the first two years after treatment. The number of participants was small, and patients still require careful long term monitoring, but the results offer families a level of hope that once seemed impossible.
That hope has a human face in Victoria Gray. Diagnosed as an infant in Mississippi, Gray endured 34 years of unpredictable and often unbearable pain. Her crises interrupted school, work, holidays, and time with her children. As an adult, she also encountered health professionals who questioned her pain or suspected she was seeking medication, an experience reported by many Black sickle cell patients.In 2019, Gray became the first person in the world to receive an experimental CRISPR treatment for sickle cell disease. The process included stem cell collection, chemotherapy, isolation, and weeks of monitoring. It was difficult, but transformative. According to a 2026 University of California, Berkeley profile, Gray has not experienced a sickle cell crisis since receiving the treatment seven years ago. She is now a patient advocate helping others understand both its promise and its demands.
Research from St. Jude Children’s Research Hospital suggests gene therapy may do more than prevent pain crises. Sickle cell disease can interfere with oxygen delivery to the brain and increase the risk of stroke. Researchers studied three patients who received gene therapy and found that elevated blood flow speed in their brains returned to normal levels. Brain blood flow improved by 22 to 43 percent after treatment.
The study was extremely small, so it does not prove that gene therapy prevents strokes. However, it provides early physiological evidence that treatment may reduce an important risk factor and protect the brain from further damage. Larger studies will be necessary to determine how long these improvements continue and which patients are most likely to benefit. 
These breakthroughs also raise a difficult question: Who will have access? Casgevy carries a list price exceeding $2 million. Treatment requires specialized facilities, chemotherapy, hospitalization, and months of recovery and monitoring. Families may also face travel expenses, lost wages, fertility concerns, and insurance restrictions.Sickle cell disease affects at least 100,000 Americans, more than 90 percent of whom are Black. Scientific progress is meaningful only when patients can reach it. The next victory must be ensuring that lifesaving innovation does not become another medical advancement placed beyond the reach of the community that needs it most. Awareness, blood donation, research participation, equitable insurance coverage, and compassionate medical care must advance alongside the science.
